In other studies, systemic administration of EHD2-sc-TNFR2 alleviated central and peripheral inflammation, reduced demyelination and neurodegeneration, improved motor symptoms, and promoted long-term recovery from neuropathic pain in an animal model of multiple sclerosis [66], while treatment with NewSTAR2, another selective TNFR2 agonist, ameliorated neuropathology and improved cognition in an Alzheimer’s disease mouse model [67]. Here, TNFRSF1B is linked to early-onset autosomal dominant Alzheimer disease.